GDRXHIGH SIGNALFINANCIAL10-K

GDRX shows alarming deterioration in balance sheet strength with current liabilities nearly doubling and cash declining 42% despite improved profitability.

The dramatic increase in current liabilities combined with the substantial cash decline suggests potential liquidity stress or significant near-term obligations that could constrain operations. While the company improved profitability, the balance sheet deterioration and increased share buybacks amid declining cash raises questions about capital allocation priorities and financial management.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

GDRX presents a mixed but concerning financial picture with current liabilities nearly doubling to $246M and cash declining 42% to $262M, creating potential liquidity pressure despite net income improving 86% to $30.4M. The company increased share buybacks by 36% to $216M while cash was declining significantly, suggesting questionable capital allocation given the balance sheet stress. The substantial increase in accounts receivable (+62%) and total liabilities (+19%) alongside declining stockholders' equity (-15%) indicates deteriorating financial stability that overshadows the operational improvements.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+184%
$1.2M→$3.5M

Capital expenditure jumped 184% — major investment cycle underway; assess returns on deployment.

Current Liabilities
Balance Sheet
+98.5%
$123.9M→$246.0M

Current liabilities surged 98.5% — significant near-term obligations; verify ability to meet short-term debt.

Net Income
P&L
+85.7%
$16.4M→$30.4M

Net income grew 85.7% — bottom-line growth signals improving overall business health.

Accounts Receivable
Balance Sheet
+61.5%
$145.9M→$235.7M

Receivables surged 61.5% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Cash & Equivalents
Balance Sheet
-41.6%
$448.3M→$261.8M

Cash declined 41.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Share Buybacks
Cash Flow
+36.2%
$158.8M→$216.4M

Share repurchases increased 36.2% — management returning capital, signals confidence in intrinsic value.

Operating Income
P&L
+32.9%
$65.8M→$87.5M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Total Liabilities
Balance Sheet
+18.7%
$663.4M→$787.8M

Liabilities increased 18.7% — monitor debt-to-equity ratio and interest coverage.

Stockholders Equity
Balance Sheet
-15%
$724.7M→$616.3M

Equity decreased 15% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 17, 2026 the registrant had 108,610,311 shares of Class A common stock, $0.0001 par value per share, and 233,964,187 shares of Class B common stock, $0.0001 par value, outstanding.
Co-Founders refers to Trevor Bezdek and Douglas Hirsch, each a director of the Company.
The term discounted price excludes prices we may otherwise source, such as prices from patient assistance programs for low-income individuals and Medicare prices, and any negotiated rates offered through our subscription offerings.
Monthly Active Consumers do not include subscribers to our subscription offerings, consumers of our GoodRx Pharma Direct (formerly pharma manufacturer solutions and referred to hereafter as "pharma direct") offering, or consumers who used our telehealth offering.
Effective January 1, 2025, Monthly Active Consumers from acquired companies are included beginning from the acquisition date.
+7 more — sign up free →
REMOVED
As of February 18, 2025 the registrant had 106,740,328 shares of Class A common stock, $0.0001 par value per share, and 276,869,320 shares of Class B common stock, $0.0001 par value, outstanding.
Co-Founders refers to Trevor Bezdek, our Co- Chairman and a director of the Company, and Douglas Hirsch, a director of the Company.
The term discounted price excludes prices we may otherwise source, such as prices from patient assistance programs for low-income individuals and Medicare prices, and any negotiated rates offered through our subscription offerings: GoodRx Gold ( Gold ), and Kroger Rx Savings Club powered by GoodRx ( Kroger Savings ) which sunset in July 2024.
Monthly Active Consumers do not include subscribers to our subscription offerings, consumers of our pharma manufacturer solutions offering, or consumers who used our telehealth offering.
Monthly Active Consumers from acquired companies are only included beginning in the first full quarter following the acquisition.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →